



Formulary Updates

Standard Drug Formulary

January 1 to March 31, 2022

Recent Drug Approvals:

Most new drug products are nonformulary until reviewed by the Pharmacy and Therapeutics Committee

Drug Name (Use)	Formulary Status/Notes
January 2022:	
Dartisla (Anticholinergic/Anitmuscarinic)	Nonformulary
Molnupiravir (Antiviral)	Preferred
Tarpeyo (Corticosteroid)	Nonformulary
Xarelto suspension (Anticoagulant)	Preferred
Zimhi (Opioid Antagonist)	Preferred, QL
February 2022	
Cibinqo (Rheumatology)	Nonformulary
Citalopram (30mg caps) (Mood)	Nonformulary
Fleqsuvy (oral susp) (Muscle Relaxant)	Nonformulary
Seglentis (Opioid/Anti-inflammatory)	Nonformulary
Twynéo (Topical, Acne)	Nonformulary
March 2022	
Mayzent (0.25mg(7),1mg) (Various inflammatory conditions)	Nonformulary
Pyrukynd (Anemia)	Nonformulary
Releuko (Neutropenia)	Nonformulary
Rinvoq (30mg, 45mg) (Various inflammatory conditions)	Preferred, Specialty, PA, QL

AL = age limit, PA = prior authorization required, QL = quantity limit ST = step therapy, OTC= over-the-counter

Pharmacy and Therapeutics (P&T) Committee Formulary Changes:

2/15/2022 2022 P&T Meeting: Changes Effective 5/2/2022	
Drug Name (Use)	Formulary Status/Notes
Asmanex (Asthma)	Non-Preferred, PA, ST *(Effective 7/1/22)
Aubagio (Multiple Sclerosis)	Preferred, Specialty, PA, QL
Basaglar (Insulin, Diabetes)	Nonformulary *(Effective 7/1/22)
Bylvay (Gastrointestinal)	Non-Preferred, QL, PA
Breztri (Respiratory)	Preferred
Fenofibric Acid (Cholesterol)	Non-Preferred, PA
Frovatriptan (Antimigraine)	Non-Preferred, PA, QL, ST
Imbruvica Tablets (280mg 140mg TABS) (Oral Oncology)	Nonformulary *(Effective 7/1/22)
Imbruvica Capsule (140mg Caps) (Oral Oncology)	Non-Preferred, Specialty, PA, QL update
Livmarli (Gastrointestinal)	Non-Preferred, QL, PA
Livtency (Anti-Viral)	Non- Preferred, PA, QL
Myfembree (Uterine Fibroids)	Preferred, PA, QL
Norditropin (Human Growth Hormone)	Nonformulary *(Effective 7/1/22)
Omnitrope (Human Growth Hormone)	Preferred, Specialty, PA *(Effective 7/1/22)
Qulipta (Antimigraine)	Non-Preferred, QL, PA
Scemblix (Oral Oncology)	Non-Preferred, PA, QL
Semglee (Insulin, Diabetes)	Preferred, QL *(Effective 7/1/22)
Sevelamer Hcl (generic Renagel) (kidney disease)	Nonformulary *(Effective 7/1/22)

2/15/2022 2022 P&T Meeting: Changes Effective 5/2/2022	
Drug Name (Use)	Formulary Status/Notes
Sevelamer carbonate Powder pack (generic Renvela) (Kidney Disease)	Preferred, PA
Trelegy Ellipta (Respiratory)	Preferred
Tudorza Pressair (Respiratory)	Non-Preferred, PA, QL
Vuity (Glaucoma)	Non-Preferred, PA, QL
Zeposia (Various inflammatory conditions)	Non-Preferred, Specialty, PA

AL = age limit, PA = prior authorization required, QL = quantity limit ST = step therapy, OTC= over-the-counter

2/15/2022 2022 P&T Meeting: No Change	
Drug Name (Use)	Formulary Status/Notes
Actemra (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL
Aimovig (Antimigraine)	Preferred, PA, QL
Ajovy (Antimigraine)	Non-Preferred, PA, QL
Biktarvy (Antiretroviral)	Preferred, Specialty
Cimzia (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL
Cosentyx (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Dupixent (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Elyxyb (Nonsteroidal Anti-inflammatory)	Nonformulary
Emgality (Antimigraine)	Preferred, PA, QL
Enbrel (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Epclusa (Antiviral)	Preferred, Specialty, PA, QL
Gvoke (Antihypoglycemic)	Preferred, QL
Humira (Various inflammatory conditions)	Preferred, Specialty, QL, PA criteria update
Insulin glargine-yfgn (Diabetes)	Nonformulary
Ipratropium Albuterol nebulizers (COPD)	Preferred, QL
Kevzara (Various inflammatory conditions)	Nonformulary
Mavyret (Antiviral)	Preferred, Specialty, PA, QL
Molnupiravir (Antiviral)	Preferred, Tier \$0, AL, QL
Nurtec ODT (Antimigraine)	Nonpreferred, PA, QL update
Orencia (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL
Oriahnn (Uterine Fibroids)	Nonformulary
Otezla (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Oxbryta (Coagulation)	Nonpreferred, PA, QL update
Paxlovid (Antiviral)	Preferred, Tier \$0, AL, QL
Recorlev (Various inflammatory conditions)	Nonformulary
Reyvow (Antimigraine)	Non-Preferred, ST, QL, PA
Rinvoq (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Siliq (Various inflammatory conditions)	Nonformulary
Simponi (Various inflammatory conditions)	Nonformulary
Skyrizi (Various inflammatory conditions)	Preferred, Specialty, PA, QL
Stelara (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL
Taltz (Various inflammatory conditions)	Nonformulary
Tavneos (Various inflammatory conditions)	Nonformulary
Tremfya (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL

Ubrelvy (Antimigraine)	Non-Preferred, ST, QL, PA
Xeljanz (Various inflammatory conditions)	Non-Preferred, Specialty, PA, QL

AL = age limit, PA = prior authorization required, QL = quantity limit, ST = Step Therapy, OTC= over-the-counter

New Generic Drugs:

The brand equivalent is nonformulary once an FDA approved generic is available

New Generic Drug (Use)	Brand Equivalent	Formulary Status/Notes
January 2022:		
Brimonidine-Timolol (Ophthalmic)	Combigan	Preferred
Dexlansoprazole DR (Reflux)	Dexilant	Non-Preferred, PA, QL
Glycopyrrolate Soln (Antimuscarinic)	Cuvposa	Non-Preferred, PA
Isotretinoin (Acne)	Absorica	Nonformulary
February 2022		
Betaine (Hypermethioninemia)	Cystadane	Non-Preferred, PA
Cyclosporine (Ophthalmic)	Restasis	Non-Preferred, PA
Maraviroc (Antiretroviral)	Selzentry	Non-Preferred, Specialty, QL, PA
March 2022		
Baclofen (Oral Soln) (Muscle Relaxant)	Ozobax	Nonformulary
Diclofenac Potassium (caps) (Nonsteroidal Anti-inflammatory)	Zipsor	Nonformulary
Digoxin (6.5mcg) (Heart)	Lanoxin (62.5mcg)	Non-Preferred, PA
Lacosamide (Anticonvulsant)	Vimpat	Preferred, ST, QL
Lenalidomide (Oral Oncology)	Revlimid	Non-Preferred, Specialty, PA, QL

AL = age limit, PA = prior authorization required, QL = quantity limit ST = step therapy, OTC= over-the-counter